Work

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report

Year: 2024

Type: article

Abstract: The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2024.1494669

Authors: Sevindzh F. Evdokimova, Anna L. Kornietskaya, Larisa V. Bolotina, Iliya V. Kolobayev, Alexander A. Fedenko, Andrey D. Kaprin

Institutions: Ministry of Health of the Russian Federation, P.A. Hertzen Moscow Oncology Research Institute, Peoples' Friendship University of Russia

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,295